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Abstract
Tumor necrosis factor receptor-related 2 (TR2, HVEM 
or TNFRSF-14) plays an important role in immune re-
sponses, however, the mechanisms regulating its ex-
pression are unclear. To understand the control of TR2 
gene expression, we studied the upstream region of 
the gene. Gel supershift assays revealed inducible 
binding of nuclear factor of activated T cells (NFAT) 
to a putative NFAT site within the TR2 promoter. 
Furthermore, cotransfection of a dominant negative 
NFAT construct, or siRNA for NFAT, resulted in in-
creased expression of a TR2 reporter gene. Our find-
ings demonstrate that NFAT negatively regulates TR2 
expression in activated T cells.
Keywords: gene expression regulation; NFATC tran-
scription factors; promoter regions, genetic; T lympho-
cytes; tumor necrosis factor ligand superfamily mem-
ber 14
Introduction
Members of the tumor necrosis factor receptor 
(TNFR) family interact with a set of ligands forming 
the TNF family. The resulting signals are involved 
in diverse cellular immune processes including 
differentiation, proliferation, and induction of apop-
totic cell death (Locksley et al., 2001). Tumor 
Necrosis Factor Receptor Related 2 (TR2, HVEM 
or TNFRSF-14) is expressed in various tissues 
and immune cells, including T cells, B cells and 
dendritic cells (DC). Signaling through TR2 pro-
motes cell proliferation and the production of 
cytokines such as interleukin 2 (IL-2), interferon-γ 
(IFN-γ), IL-4, and TNF-α (Croft, 2003). TR2 
interacts with LIGHT (TL5 or TNFSF-14) (Kwon et 
al., 1999) and B- and T-lymphocyte attenuator 
(BTLA) (Krieg et al., 2007), and modulates T 
cell-mediated immune responses in tumors, graft- 
versus-host-disease (GVHD), and graft rejection 
(Ye et al., 2002).
    Members of the nuclear factor of activated T 
cells (NFAT) family are widely expressed in cells of 
the immune system, including T cells. They are 
involved in T cell regulation (Rengarajan et al., 
2002), and the expression of many inducible 
genes, including not only cytokines such as IL-4, 
and IFN-γ (Yoshida et al., 1998) but also TNF 
family members such as TNF-α, and LIGHT 
(Macian, 2005). In resting T cells, NFAT proteins 
reside in the cytoplasm, and upon activation trans-
locate to the nucleus (Wisniewska et al., 2007). 
The nuclear translocation of NFAT proteins is 
controlled by calcineurin (CaN), a Ca2+-dependent 
phophatase, and CaN is highly sensitive to cyclo-
sporine A (CsA) (Shaw et al., 1995), which pre-
vents CaN-dependent nuclear translocation of NFAT.
    Ye et al. (2002) reported that treatment with 
CsA, combined with inhibition of the LIGHT-TR2 
interaction using either LIGHT knockout mice or 
blocking antibody against TR2, prevented acute 
allograft rejection. The combined treatment suppre-
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Figure 1. Effect of CsA on TR2 gene expression in primary murine CD4+
T cells and the EL-4 T cell line. Purified CD4+ T or EL-4 T cells were in-
cubated in the presence or absence of cyclosporin A (400 ng/ml), and 
TR2 expression was assessed by FACS or RT-PCR. (A) Murine CD4+ T 
cells or (B) EL-4 cells were stained with anti-TR2 mAb (12H9, rat IgG2b) 
and FITC-conjugated secondary antibodies, and levels of TR2 ex-
pression were determined by FACS analysis. Negative controls with iso-
typic-matched antibody were indicated in thick line (A) or shaded histo-
gram (B). (C) Total RNA was prepared from EL-4 cells and analyzed by 
reverse transcript-PCR using mTR2 (27 cycles) and GAPDH (30 cycles) 
primer pairs in non-saturating conditions. (D) Expression of TR2 protein 
was determined by Western blot analysis.
ssed the upregulation of many cytokines in the 
grafts, including IFN-γ, IL-2, and TNF-α. Intere-
stingly, T cells were still activated after trans-
plantation in the presence of CsA, and TR2 was 
involved in the activation process, although the 
effects of CsA on TR2 have not been determined. 
Based on these observations, we hypothesized 
that TR2 molecules are expressed on T cells in the 
presence of CsA, and that the expression of TR2 
on T cells is increased by CsA.
    TR2 is expressed constitutively on the surface of 
resting T cells and its level of expression decre-
ases after activation (Morel et al., 2000); however, 
the mechanism by which it is down regulated after 
activation is not well understood. In this study, we 
report that NFAT is a negative regulator of TR2 
expression in activated T cells.
Results
TR2 expression is increased by treatment with Cs A
TR2 is expressed constitutively on the surface of 
resting T cells, and expression decreases after 
activation (Morel et al., 2000). Also inhibition of the 
LIGHT-TR2 interaction in the presence of CsA 
prevents acute allograft rejection (Ye et al., 2002). 
Therefore, although the effects of CsA on the 
immune system are complex, we hypothesized that 
it affects TR2 expression. As shown in Figure 1A, 
TR2 protein was expressed in resting primary 
CD4+ T-cells of B57/BL6 mice, and expression was 
increased by treatment with CsA. Incubation of 
EL-4 T cells with CsA also resulted in increased 
expression of TR2 (Figure 1B). To determine 
whether TR2 expression was affected at the trans-
criptional level, we analyzed TR2 mRNA levels by 
RT-PCR. As shown in Figure 1C, TR2 mRNA in 
EL-4 T cells decreased in response to treatment 
with PMA/ionomycin (PMA plus ionomycin) and 
increased when the cells were treated with 
PMA/ionomycin in the presence of CsA. The effect 
of CsA on TR2 expression was also assayed by 
Western blot analysis with anti-TR2 antibody 
(Figure 1D) at 12 and 24 h after PMA/ionomycin 
treatment because of the major differences in the 
RT-PCR results. The protein level of TR2 was also 
decreased by treatment with PMA/ionomycin and 
increased by CsA. These experiments point to the 
presence of negative regulators of TR2 expression. 
An NFAT binding site in the mTR2 promoter is 
responsible for negative regulation
In a previous study (Sul et al., 2008) we reported 
that the -273/-3 upstream region of the TR2 gene 
was important in TR2 gene regulation. Further 
analysis of this region revealed that deletion of 
nucleotides -81 to -76 (Figure 2A, D1) resulted in a 
major increase in the activity of a luciferase 
reporter gene, pointing to the presence of a nega-
tive regulatory element in this interval. Further-
more, changing the TTCCTT sequence to TTAATT 
(Figure 2B, M1) resulted in comparable activity to 
that of the D1 deletion. The TTCCTT sequence is 
identical to the NFAT-binding site generated by the 
nuclear factor search program TESS (Schug and 
Overton, 1997). The activity of NFAT proteins is 
regulated by CaN, which is highly sensitive to the 
immunosuppressive drug CsA, which prevents 
CaN-dependent nuclear translocation of NFAT. 
Since we had found that CsA increases expression 
of TR2 in T cells, we investigated the effect of CsA 
on EL-4 cells transfected with TR2 promoter 
reporter constructs. As demonstrated in Figure 2C, 
the luciferase activity of the construct pTR2(-276/-3) 
decreased when cells were activated with PMA/ 
ionomycin, and increased in a dose-dependent 
manner upon treatment with CsA. On the other 
hand, exposure of cells harboring the deletion 
construct D1 to PMA/ionomycin or CsA did not 
alter promoter activity. These results strongly 
suggest involvement of NFAT in regulating TR2 
expression.
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Figure 2. Analysis of the activity of the TR2 promoter and its mutant 
forms in EL-4 cells. EL-4 cells were transiently transfected with the vari-
ous constructs, and also with pCMV-β-gal as a control for transfection 
efficiency. Luciferase activity was measured 24h after transfection. 
Relative activities were compared with that of the pTR2(-276/-3) 
construct. This construct was used as the wild type (Wt) construct in sub-
sequent experiments. (A) The deletion mutant construct (D1) was gen-
erated from the Wt construct by deleting; the putative NFAT site (from 81 
to -76), shown underlined. (B) The substitution mutant construct (M1) 
was derived from the Wt by replacing the two underlined bases. (C) The 
effects of PMA/ionomycin and CsA on the expression of the luciferase 
construct were assayed with the designated mTR2 reporter constructs 
(Wt or D1). Luciferase assays were repeated at least three times. 
    To confirm this role of NFAT, we performed 
EMSAs with primary CD4+ T cells from C57/BL6 
mice. As shown in Figure 3A, nuclear extracts of 
resting CD4+ T cells formed a complex, C1 (Figure 
3A, lane 1) with 32P labeled oligonucleotide P2 
containing the wild type NFAT binding site (see 
Methods), and activation with PMA/ionomycin re-
sulted in the formation of an additional complex, 
C2 (Figure 3A, lane, 2, 3, and 4). Cold P2 probe 
(the putative NFAT site) inhibited binding of 32P 
labeled P2 whereas cold P1 and P3 probes did not 
(Figure 3B, lanes 1-4). Excess unlabelled com-
mercial NFAT probe (Santa Cruz) also inhibited 
binding of the P2 probe (Figure 3B, lane 5). 
Substitution of AA for CC at positions -78 and -79 
in the P2 probe (P2M) resulted in loss of 
competition with P2, indicating that the interaction 
was sequence specific (Figure 3B, lane 6). When 
CD4+ T cells were treated with CsA along with 
PMA/ionomycin the C2 complex was not formed 
(Figure 3C, lane 2). These results indicate that 
NFAT binds to the TR2 promoter after activation 
with PMA/ionomycin. To show that NFAT is re-
cruited to the TR2 promoter, we performed su-
pershift assays. These confirmed that NFATc2 
binds to the TR2 promoter of activated CD4+ T 
cells (Figure 3D, lane 3, arrow C3) since mono-
clonal antibody against NFATc2 supershifted the 
C2 complex induced by PMA/ionomycin. To study 
the effect of the different NFATs, CD4+ T cells were 
harvested after various times of treatment with 
PMA/ionomycin. As demonstrated in Figure 3E, 
binding of NFATc1 and NFATc2 was evident 15 min 
after activation, and only NFATc1 binding was 
increased after 20 h of activation whereas no 
binding of NFATc3 was detected.
    We also performed EMSA assays with EL-4 T 
cells. In contrast with the CD4+ T cells, in which the 
C2 complex appeared after treatment with PMA/ 
ionomycin, nuclear extracts of EL-4 T cells con-
tained the C2 complex in the absence of treatment 
with PMA/ionomycin (Figure 4A, lane 1), and the 
C2 complex was supershifted by the anti-NFATc2- 
Ab to form complex C3 (Figure 4A, lane 3). The 
supershift patterns of cells exposed to PMA/ 
ionomycin for 20h were almost identical to those of 
cells not exposed to PMA/ionomycin (Figure 4B).
    To confirm that TR-2 production is regulated by 
NFAT, we constructed a dominant negative NFAT 
mutant (dnNFAT) and measured TR2 expression 
using the reporter construct. The dnNFAT was 
derived from NFAT3 and consisted of N-terminal 
amino acid residues 1 to 160, which, according to 
Chow et al. (1999), have dominant negative activity 
against all four known NFATs (NFATc1, c2, c3, and 
c4). As shown in Figure 4C, co-transfection of EL-4 
cells with the dnNFAT construct and the TR-2 
reporter gene resulted in increased reporter gene 
activity. We also demonstrated the effect of NFAT 
on TR2 regulation using siRNA. The siRNA was 
constructed for NFATc2 because we found that 
only NFATc2 interacted with the TR2 promoter in 
EL-4 T cell (Figure 4A and 4B). As demonstrated in 
Figure 4D, transfection with NFATc2 siRNA incre-
ased reporter gene activity.
Discussion
While the biological importance of TR2 is clear 
from studies demonstrating its role in T cell 
activation and regulation, relatively little is known 
about the factors that affect its expression in T 
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Figure 3. NFAT molecules bind to the TR2 gene promoter in CD4+ T cells, and their recruitment is affected by CsA. (A) 
EMSAs were performed using nuclear extracts from CD4+ T cells which were either in the resting state (lane 1) or acti-
vated with PMA/ionomycin for 5 or 30 min and 5.0 h (lane 2-4). Arrows identify retarded complexes putatively contain-
ing NFATs (C1, C2) (B) A nuclear extract from activated CD4+ T cells that had been activated with PMA/ionomycin for 
30 min, was used in a competition experiment: a 100-fold molar excess of unlabeled P2 competitor oligonucleotide was 
included in the assays as indicated. P2M is a mutant of P2 with AA substituted for CC (bold, underlined). NFAT STD re-
fers to a commercial NFAT probe (Santa Cruz). (C) The effect of CsA added together with PMA/ionomycin on the for-
mation of the complex with probe P2. (D) Supershift assays were performed using anti-NFATc1, c2, and c3 antibodies. 
A nuclear extract of PMA/ionomycin-activated CD4+ T cells (for 15 min) was used along with probe P2. Arrows identify 
the specific supershift complexes corresponding to the NFATs (C3). (E) Recruitment of NFAT components in nuclear 
extracts of CD4+ T cells activated with PMA/ionomycin for 15 min, 5 h, and 20 h. Supershift assays were performed us-
ing antibodies; none for lane 1, 2, 6, and 10; anti-NFATc1 for lane 3, 7 and 11; anti-NFATc2 for lane 4, 8 and 12; an-
ti-NFATc3 for lane 5, 9 and 13.
cells. In a previous study (Sul et al., 2008) we 
reported that the -273/-3 region of the TR2 gene 
contained binding sites for regulatory factors. In 
this report, we studied the region involved in 
negative regulation.
    Of the NFAT family members, NFATc1 and 
NFATc2 are expressed predominantly in lympho-
cytes, and NFATc3 is also expressed in T cells 
(Rengarajan et al., 2002; Macian, 2005). NFATc1 is 
induced by signals such as TCR stimulation, while 
NFATc2 and NFATc3 are expressed constitutively 
and their expression is increased by T cell activat-
ion (Rengarajan et al., 2002). Using EMSAs, we 
demonstrated that NFATc2 was recruited to the 
TR2 promoter as soon as CD4+ T cells were 
activated by PMA/ionomycin. NFATc1 also became 
bound to the TR2 promoter as T cell activation 
proceeded, and binding of these factors were 
decreased by treatment with CsA. Thus, binding of 
the NFATs to the TR2 promoter site in activated T 
cells is associated with decreased TR2 trans-
cription.
    NFAT proteins are involved in T cell differentiat-
ion and T cell activation. However, their functions 
are rather controversial, and they also play nega-
tive roles. It has been reported that NFATc1 is 
required for TH2 cell differentiation, whereas loss of 
NFATc2 diminishes TH1 cell differentiation and 
causes a mild bias towards TH2 cell differentiation, 
probably because the T cells of NFATc2 deficient 
mice maintain IL-4 production for longer (Kiani et 
al., 1997; Yoshida et al., 1998; Macian, 2005). 
NFATc2 downregulates cyclin-dependent kinase 4 
(CDK4) by directly binding and repressing its 
transcription through the recruitment of histone 
deacetylase (Baksh et al., 2002).
    NFATs act synergistically with other proteins 
(Lim et al. 2008) such as AP-1 (Wisniewska et al., 
2007), and IRF (Hu et al., 2002). Although we have 
reported that IRF molecules are involved in TR2 
regulation (Sul et al., 2008), the interaction of 
NFATs with other proteins, and the precise mecha-
nism of regulation of TR2 gene expression, require 
further investigated.
    Although our results demonstrate that NFATs are 
involved in regulating TR2 expression after T cell 
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Figure 4. NFAT molecules bind to the TR2 gene promoter in EL-4 T 
cells, and TR2 promoter activity is affected by dnNFAT and siRNA. (A) 
EMSAs were performed using nuclear extracts from EL-4 T cells without 
treatment with PMA/ionomycin (lane 1), and supershift assays were per-
formed using anti-NFATc1, c2, c3, c4, and c5 (lane 2, 3, 4, 5, and 6). 
Arrows identify retarded complexes putatively formed by NFATs (C1, C2, 
C3). (B) Recruitment of NFAT components measured in nuclear extracts 
of EL-4 T cells activated with PMA/ionomycin for 15 min (lane 2-5), 5 h 
(lane 6-9), and 20 h (lane 10-13). The letters c1, c2, c3 refer to anti-NFAT 
c1, c2, and c3 antibodies, respectively. (C) TR2 promoter activity was 
measured using the luciferase reporter plasmid pTR2(-276/-3) co-
transfected into EL-4 T cells with various concentrations of dnNFAT; as a 
control, dnNFAT was omitted. Cells were harvested 24 h after trans-
fection, and luciferase activity was measured with the dual luciferase as-
say system (Promega). It was normalized to β-galactosidase activity and 
is expressed as percentages of the activity with Wt in the absence of 
dnNFAT. (D) RNA knockdown experiments were performed. EL-4 cells 
were transfected by electroporation with a siRNA duplex and the TR2 
promoter-driven luciferase construct. The transfection efficiency of the 
siRNA was measured by Western blot analysis using mAb for NFATc2 
(Top). TR2 promoter activity was measured using the luciferase re-
porter plasmid pTR2(-276/-3) cotransfected into EL-4 T cells with
NFATc2-specific siRNA; as a control, nonspecific siRNA was used 
(Bottom). Luciferase activity was measured as in C.
activation, the factors regulating TR2 expression in 
resting T cells are still obscure. In EL-4 T cells, 
expression of reporter genes was upregulated in 
mutant forms of the pTR2(-276/-3) construct 
(Figure 2A and 2B) or by transfection of dnNFAT or 
siRNA-NFATc2 (Figure 4C and 4D) without PMA/ 
ionomycin treatment. This may be explained by the 
fact that the C2 complex is formed in EL-4 T cells 
without PMA/ionomycin treatment, and is super-
shifted with anti-NFATc2 antibody. However, in 
resting CD4+ T cells we failed to detect any NFAT 
isoforms, including NFAT5, in the complexes 
formed in gel shift assays (data not shown).
    As reported previously (Morel et al., 2000), and 
confirmed by us, TR2 is expressed constitutively in 
resting T cells and is down regulated after activat-
ion with PMA/ionomycin. We have demonstrated 
above that CsA, by inhibiting the nuclear translo-
cation of NFAT proteins, increases the expression 
of TR2. Our results indicate that NFATs act as 
negative regulators of TR2 expression in activated 
T cells.
Methods
CD4+ T cell purification and stimulation
Cell suspensions were prepared from the spleens and 
lymph nodes of B57/BL6 mice, and incubated at 37oC for 1 
h in flasks to eliminate adherent cells. CD4+ T cells were 
then purified using a MACS magnetic separation system 
according to the manufacturer’s instructions (Miltenyl 
Biotech), and LS columns were used to select the CD4+ T 
cells. These proved to be routinely ＞ 95% pure by flow 
cytometry. 
Cell culture and transfection experiments
The EL-4 T-cell line was grown in RPMI 1640 medium 
supplemented with 10% fetal calf serum. For transfection, 
aliquots of 107 cells were electroporated at 950 micro-
farads and 300 V using a Bio-Rad Gene Pulser in the 
presence of 25 μg of pGL2/basic vector or the TR2 
promoter-driven luciferase constructs, together with 5 μg of 
the beta-galactosidase vector. Luciferase activity was 
determined using the Promega luciferase reporter assay 
and a Dynex luminometer. Data were normalized to beta- 
galactosidase activity. Reported values are the averages of 
three independent transfections, with standard deviations.
Western blot analysis
Cells were lysed and separated on 10% SDS-PAGE gels, 
transferred to PVDF membranes (Invitrogen), blotted with 
antibody specific to TR2 (9A3, Immunomics) or NFATc2 
(sc-7296x, Santa Cruz), and detected with an ECL 
detection system (Pierce).
Preparation of reporter gene constructs, expression 
vectors, and dnNFAT
The genomic sequence upstream of the murine TR2 gene 
pTR2(-276/-3)-luc (relative to ATG at n1) was prepared as 
described previously (Sul et al., 2008). The dnNFAT DNA 
was cloned from EL-4 cells and inserted into pCDNA using 
primers 5’-GAGCTCATGGGGGCCGCAAGC-3’ (sense) 
and 5’-GTCGACGACGACCTCCAGCCTCTC-3’ (antisense). 
The cloned domain comprises residues 1 to 160, which 
include the NFAT transcription activation domain (TAD) 
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(Chow et al., 1999).
Electrophoretic mobility shift assays (EMSAs)
Nuclear extracts of 107 EL-4 T cells were subjected to 
EMSAs using probes labeled with [γ-32P]ATP using T4 
nucleotide kinase. The reaction mixtures were loaded 
directly onto 6% non-denaturing polyacrylamide gels and 
electrophoresed at a constant voltage of 200 V at 4oC. The 
double stranded oligonucleotides used as probes were as 
follows: wild type NFAT binding site (P2), 5’-TTTCACTT-
TTCCTTGCCAAG-3’; mutated form of P2 (P2M), 5’-TTT-
CACTTAACCTTGCCAAG-3’; and control NFAT binding 
site in the IL-2 promoter (NFAT-STD), 5’-TATGAAACA-
AATTTTCCTCTTTGGGCG-3’ (Santa Cruz). For supershift 
assays, 1 μg aliquots of monoclonal antibodies against 
NFATc1 (sc-7294x), NFATc2 (sc-7296x), or NFATc3 (sc- 
8405x) were added to binding reaction mixtures at room 
temperature prior to electrophoresis. The reaction mixtures 
were loaded directly onto a 5% non-denaturing polyacry-
lamide gel and electrophoresed at room temperature at a 
constant voltage of 70 V.
Transfection of siRNA into EL-4 cells
RNA knockdown experiments were performed using 
chemically synthesized and annealed small interfering 
RNAs (siRNA) specific for NFATc2, and negative control 
siRNA duplexes; both were purchased from Bioneer 
(1391490 and SN-1001, respectively). 107 EL-4 cells were 
transfected by electroporation with 200 nM siRNA duplex, 
25 μg of the TR2 promoter-driven luciferase construct and 
5 μg of the beta-galactosidase plasmid.
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